Share on StockTwits

Illumina (NASDAQ:ILMN)‘s stock had its “outperform” rating restated by investment analysts at Credit Suisse in a note issued to investors on Thursday. They currently have a $198.00 price objective on the stock, up from their previous price objective of $180.00. Credit Suisse’s price objective points to a potential upside of 9.61% from the company’s current price.

Shares of Illumina (NASDAQ:ILMN) traded down 4.15% on Thursday, hitting $173.15. 1,960,128 shares of the company’s stock traded hands. Illumina has a 52-week low of $72.77 and a 52-week high of $184.49. The stock has a 50-day moving average of $173.3 and a 200-day moving average of $155.6. The company has a market cap of $22.232 billion and a P/E ratio of 127.03.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Wednesday, July 23rd. The company reported $0.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter last year, the company posted $0.43 earnings per share. Illumina’s revenue was up 29.5% compared to the same quarter last year. Analysts expect that Illumina will post $2.17 EPS for the current fiscal year.

In other Illumina news, SVP Nicholas Naclerio unloaded 2,000 shares of Illumina stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $174.26, for a total value of $348,520.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Illumina in a research note on Thursday. They now have a $230.00 price target on the stock, up previously from $190.00. Separately, analysts at Macquarie reiterated an “outperform” rating on shares of Illumina in a research note on Thursday. They now have a $200.00 price target on the stock, up previously from $177.00. Finally, analysts at Mizuho raised their price target on shares of Illumina from $200.00 to $220.00 in a research note on Thursday. They now have a “buy” rating on the stock. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Illumina presently has an average rating of “Buy” and an average target price of $170.58.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.